RWMG
TSHA icon

Redwood Wealth Management Group’s Taysha Gene Therapies TSHA Stock Holding History

Redwood Wealth Management Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,700
Closed -$246K – 190
2025
Q4 		$246K Buy
+44,700
New +$217K 0.1% 158
2024
Q3 		– Sell
-46,400
Closed -$104K – 1013
2024
Q2 		$104K Buy
+46,400
New +$135K 0.08% 187
2024
Q1 		– Sell
-42,600
Closed -$75.4K – 142
2023
Q4 		$75.4K Buy
42,600
+4,400
+12% +$8.77K 0.08% 125
2023
Q3 		$121K Buy
38,200
+150
+0.4% +$280 0.14% 121
2023
Q2 		$25.2K Buy
38,050
+300
+0.8% +$217 0.03% 145
2023
Q1 		$30.1K Buy
37,750
+2,150
+6% +$2.78K 0.03% 150
2022
Q4 		$80.5K Buy
+35,600
New +$72.1K 0.1% 127

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Redwood Wealth Management Group's TSHA Position: Q1 2026 in Review

Redwood Wealth Management Group sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 44,700 shares — an estimated $246K sold.

Redwood Wealth Management Group first reported a position in TSHA in Q4 2022 and held it in 7 quarters. The position peaked at $246K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Redwood Wealth Management Group reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Redwood Wealth Management Group sold 44,700 Taysha Gene Therapies shares in Q1 2026, an estimated $246K.
  • Redwood Wealth Management Group first reported a position in Taysha Gene Therapies in Q4 2022 and held it in 7 quarters.
  • Redwood Wealth Management Group's Taysha Gene Therapies position peaked at $246K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Redwood Wealth Management Group's 13F filing for Q1 2026, filed 24 Apr 2026.